Geode Capital Management LLC Raises Stock Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Geode Capital Management LLC increased its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 9.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,071,761 shares of the company's stock after acquiring an additional 89,032 shares during the period. Geode Capital Management LLC owned about 0.28% of GoodRx worth $4,986,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. National Bank of Canada FI increased its holdings in GoodRx by 34.9% in the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock valued at $39,000 after purchasing an additional 2,151 shares during the last quarter. Versor Investments LP bought a new position in GoodRx during the 4th quarter worth $54,000. Verus Capital Partners LLC acquired a new position in GoodRx during the 4th quarter valued at about $55,000. Steward Partners Investment Advisory LLC acquired a new position in shares of GoodRx during the fourth quarter valued at approximately $56,000. Finally, EntryPoint Capital LLC bought a new stake in shares of GoodRx during the 4th quarter worth $56,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Truist Financial reduced their price objective on GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research report on Thursday, April 10th. Wells Fargo & Company cut their price objective on GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Tuesday. KeyCorp lowered their price objective on GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Finally, Citigroup decreased their target price on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a research report on Friday, January 10th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, GoodRx currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.84.

GoodRx Stock Up 1.0 %

GDRX stock traded up $0.05 on Thursday, hitting $4.68. 127,894 shares of the company's stock were exchanged, compared to its average volume of 1,373,721. The firm has a 50 day moving average price of $4.56 and a two-hundred day moving average price of $4.86. The stock has a market cap of $1.79 billion, a P/E ratio of -156.17, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. GoodRx Holdings, Inc. has a 12-month low of $3.82 and a 12-month high of $9.26. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.